Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin

doi:10.1084/jem.155.3.949

This Article

	Full Text (PDF, 460K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Vallera, D. A.
	Articles by Kersey, J. H.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Vallera, D. A.
	Articles by Kersey, J. H.


Social Bookmarking

	What's this?

ARTICLES

Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin

DA Vallera, RJ Youle, DM Neville Jr and JH Kersey

A new method has been devised to eliminate T cells from murine bone marrow grafts across major histocompatibility barriers and thus prevent graft-vs.-host disease (GVHD). The method utilizes a monoclonal antibody directed at the Thy-1.2 antigen but is complement independent. To make anti-Thy-1.2 toxic, the antibody is covalently linked to the toxin ricin. Ricin ordinarily binds, enters, and kills cells through receptors containing galactose. The hybrid protein, anti-Thy-1.2-ricin, can enter and kill cells via the Thy-1.2 receptor. In the presence of lactose the usual entry route for ricin is largely blocked and the hybrid is shown to be a highly selective reagent that is T cell specific in its inhibition of mitogen-stimulated splenocytes. We have used a model of severe and fatal GVHD where BALB/c splenocytes and bone marrow cells are given to irradiated C57BL/6 recipients. Over 90% of these mice die by day 70, exhibiting signs of GVHD. When donor cells are pretreated with 0.5 microgram/ml of anti-Thy-1.2-ricin plus 200 mM lactose before injection, 10 of 11 animals survive through day 70 without signs of GVHD. These studies demonstrate that ricin linked to monoclonal antibodies may have utility related to the prevention of GVHD in human bone marrow transplantation.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Drobyski, W. R., Morse, H. C. III, Burns, W. H., Casper, J. T., Sandford, G. (2001). Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. Blood 97: 2506-2513 [Abstract] [Full Text]
Drobyski, W. R., Majewski, D., Ozker, K., Hanson, G. (1998). Ex Vivo Anti-CD3 Antibody-Activated Donor T Cells Have a Reduced Ability to Cause Lethal Murine Graft-Versus-Host Disease but Retain Their Ability to Facilitate Alloengraftment. J. Immunol. 161: 2610-2619 [Abstract] [Full Text]
Vitetta, E., Fulton, R., May, R., Till, M, Uhr, J. (1987). Redesigning nature's poisons to create anti-tumor reagents. Science 238: 1098-1104 [Abstract]
Vallera, D., Ash, R., Zanjani, E., Kersey, J., LeBien, T., Beverley, P., Neville, D. Jr, Youle, R. (1983). Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science 222: 512-515 [Abstract]
Vitetta, E., Krolick, K., Miyama-Inaba, M, Cushley, W, Uhr, J. (1983). Immunotoxins: a new approach to cancer therapy. Science 219: 644-650
SEEGER, R. C., SIEGEL, S. E., SIDELL, N. (1982). Neuroblastoma: Clinical Perspectives, Monoclonal Antibodies, and Retinoic Acid. ANN INTERN MED 97: 873-884 [Abstract]